SecBot SecBot
PRESS-RELEASE ·Filed Apr 1, 2026

CLDX

Celldex Therapeutics, Inc.
NEUTRAL
Impact 5/10
Horizondays Processed7mo ago WireGlobeNewswire
Press release · Offering
Actionable Insight • Neutral

Traders should monitor for potential short-term downward pressure due to share dilution, though the capital strengthens the balance sheet for upcoming commercial and clinical milestones. The use of proceeds supports long-term value creation if barzolvolimab gains approval and achieves market uptake.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$31.06
T+0 close · Apr 1, 2026 · via day close
Latest settled
+19.80%
T+60 · $37.21
Vs SPY
+5.64%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 2 $31.06entry
  2. T+1 · 8mo ago +1.00%α +0.52% · $31.37
  3. T+5 · 7mo ago +3.80%α +0.18% · $32.24
  4. T+20 · 7mo ago +5.86%α −4.02% · $32.88
  5. T+60 · 5mo ago +19.80%α +5.64% · $37.21
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Celldex Therapeutics priced a public offering of 10,345,000 shares at $29.00 per share, raising approximately $300 million in gross proceeds. The company may sell an additional 1,551,750 shares via an underwriter option, and plans to use the funds for commercial readiness of barzolvolimab, clinical development, and general corporate purposes.

Key Financial Metrics

Deal Value
$300.0M

Key Facts

  • Celldex is offering 10,345,000 shares at $29.00 per share.
  • Gross proceeds expected: ~$300 million (excluding underwriter option).
  • Underwriters have a 30-day option to purchase up to 1,551,750 additional shares.
  • Proceeds will fund commercial launch of barzolvolimab (if approved), clinical development, platform expansion, and general corporate needs.
  • Offering expected to close April 6, 2026, subject to customary conditions.

Financial Impact

$300 million gross proceeds, with potential for $44.5 million more if underwriters fully exercise their option (total ~$344.5M). Dilution estimated at ~10.5% of current market cap ($2.1B).

dilutioncashequity

Risk Factors

  • Dilution from new share issuance may pressure stock price near closing.
  • Forward-looking statements carry uncertainty around future commercial and clinical outcomes.
  • Market conditions could affect final execution if underwriters exercise their option.

Market Snapshot

Exchange
Nasdaq
Sector
In Vitro & In Vivo Diagnostic Substances

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3267105

Track record

21 reports on CLDX

Performance horizon

4 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +19.96% at T+20 after the Jun 14, 2026 report. 4 of 8 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $28.97 Now $28.59 −1.31% settles Feb 12
  2. Nov 5, 202611d ago S-3ASR Neutral 3/10 Entry $29.87 Now $28.59 −4.29% settles Feb 4
  3. Nov 5, 202611d ago 8-K Neutral 5/10 Entry $29.87 Now $28.59 −4.29% settles Feb 4
  4. Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $29.71 Now $28.59 −3.77% settles Feb 1
  5. Oct 7, 20265w ago SC 13G/A Neutral 3/10 Entry $30.43 Now $28.59 −6.05% settles Jan 4
  6. Sep 22, 20267w ago Institutional Cluster Bullish 4/10 Entry $33.51 Now $28.59 −14.68% settles Dec 16
  7. Sep 22, 20267w ago 8-K Bullish 7/10 Entry $33.51 Now $28.59 −14.68% settles Dec 16
  8. Sep 22, 20267w ago Press Release Bullish 7/10 Entry $33.51 Now $28.59 −14.68% settles Dec 16
  9. Jun 14, 202622w ago Press Release Bearish 6/10 Entry $32.12 to $38.10 Now $28.59 +10.99% ▼ −18.62% −18.22% vs SPY
  10. Jun 14, 202622w ago Press Release Bullish 7/10 Entry $32.12 to $38.10 Now $28.59 −10.99% ▲ +18.62% +18.22% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens Wed (11h 38m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 1, 2026